In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Adar Poonawalla, CEO, Serum Institute of India, on life after Covid, vaccine pricing, and expansion into new frontiers.

The EMA now advises against using the drug for people aged over 65 after 17 serious adverse effects were recorded in this age ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

Infectious disease stocks stumbled in the early months of 2025, with the BioWorld Infectious Disease Index (BIDI) plunging 17.83% by the end of April, well behind the broader markets. By comparison, ...

(Reuters) - The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.

In a health alert, the Centers for Disease Control and Prevention and the Food and Drug Administration said people 60 years of age and older should skip getting Valneva-developed Ixchiq vaccine ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events. As of May 7, 17 serious events, including two deaths, have been reported ...